Trial Profile
Using TOfogliflozin for Possible better Intervention against Atherosclerosis for Type 2 Diabetes Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs Tofogliflozin (Primary) ; Antihyperglycaemics
- Indications Atherosclerosis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms UTOPIA
- 16 Jun 2020 Primary endpoint (Changes in the IMT value (mean and max IMT) during a 104-week treatment period measured by carotid arterial echography Particularly focusing on the change of the mean of right and left meanIMT during 104 weeks of the study period) has not been met, as per results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 05 Jul 2019 Status changed from active, no longer recruiting to completed.